Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Eva M. Volf"'
1
Pediatric Psoriasis: An Emphasis on Treatment
Autor: Eva M. Volf, Shiu-Chung Au
Publikováno v: Psoriasis Forum. :26-35
Childhood psoriasis is a common chronic disease that may have devastating physical and psychosocial consequences. Most children are treated with topical agents, including corticosteroids, coal tars, anthralin, calcipotriene, and tazarotene. For moder
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a2cc66e6ab154d8848d5262b5d5e504
https://doi.org/10.1177/247553031016a00204
Zobrazit plný text záznamu
2
Prevalence of the metabolic syndrome in children with psoriatic disease
Autor: Catherine D Buzney, Daniel S. Loo, Paul F. Lizzul, Eva M. Volf, Danielle Levine, Andrew C. Wang, Jorge M. Lopez-Benitez, Alice B. Gottlieb, John Kulig, Manasa Bhandarkar, Todd Kerensky, Ari M. Goldminz, Laurie C. Miller, Shimrat Yaniv, Mary E. Brown, Noori Kim, Nicole Dumont, Shiu-chung Au
Publikováno v: Pediatric dermatology. 30(6)
Adults with psoriasis have a greater risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), but few studies have investigated the prevalence of MetS and other risk factors for CVD in children with psoriasis. In an assessor-bli
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969a23d83993cd2c5a7087562cde93f1
https://pubmed.ncbi.nlm.nih.gov/24016334
Zobrazit plný text záznamu
3
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis
Autor: Eva M, Volf, Shiu-Chung, Au, Nicole, Dumont, Pamela, Scheinman, Alice B, Gottlieb
Publikováno v: Journal of drugs in dermatology : JDD. 11(3)
Evaluate the efficacy and safety of apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, in subjects with recalcitrant moderate to severe atopic dermatitis (AD) or allergic contact dermatitis (ACD).This was a proof-of-concept, phase 2, open-labe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::724ec1c38b2effe5701c097ca5a0871e
https://pubmed.ncbi.nlm.nih.gov/22395585
Zobrazit plný text záznamu
4
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis
Autor: Eva M. Volf, Melissa A Michelon, Noori Kim, Andrew C. Wang, Paul F. Lizzul, Israel D. Andrews, Ari M. Goldminz, Shimrat Yaniv, Todd Kerensky, Meghan T. Hession, Alice B. Gottlieb, Nicole Dumont, Shiu-chung Au
Publikováno v: The Journal of dermatological treatment. 24(3)
Palmoplantar psoriasis is a variant of psoriasis resistant to many forms of treatment.Twenty subjects with moderate-to-severe psoriasis of the palms and soles, 50% with pustules at baseline, were treated with ustekinumab at weeks 0, 4, and 16. All su
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526b96c3dff7ec045b7f26312f1cbf75
https://pubmed.ncbi.nlm.nih.gov/22390688
Zobrazit plný text záznamu
6
Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts
Autor: Eva M, Volf, Danielle E, Levine, Melissa A, Michelon, Shiu-Chung, Au, Eshan, Patvardhan, Nicole, Dumont, Daniel S, Loo, Jeffrey, Kuvin, Alice B, Gottlieb
Publikováno v: Journal of drugs in dermatology : JDD. 10(8)
Adult patients with psoriasis have an increased prevalence of the metabolic syndrome (MetS) and cardiovascular disease (CVD) risk factors due to elevations of Tumor Necrosis Factor and other inflammatory cytokines.1,2 Recently, higher rates of hyperl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::41aa80fa58424a04084b473cffab8a5a
https://pubmed.ncbi.nlm.nih.gov/21818512
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje